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E D I T O R I A L
Resisting resistance to cancer immunotherapy
Cancer immunosurveillance is the process of an intact
immune system detecting and eradicating neoplastic cells.
Immunoediting is a process by which a tumor cell over-
comes the process of tumor elimination, going through a
period of equilibrium with the immune system and eventu-
ally leading to tumor escape.1 Research conducted during
the past three decades has exposed a myriad of pathways
exploited by human malignancies to evade immunological
destruction. Most notably, inhibitory immune checkpoints
such as CTLA-4 and PD-1/PD-L1, which normally main-
tain peripheral tolerance by disabling the activation and
effector functions of autoreactive T-cells, have been found
to be co-opted in a majority of common cancer types.
Establishing the clinical efﬁcacy of monoclonal antibodies
that neutralize these pathways has represented a signiﬁcant
step forward in incorporating immunotherapy into the
anti-cancer armamentarium.
Unfortunately, a well-known contrivance of neoplasia is
to continuously evolve and become resistant to anticancer
therapies. Observations of acquired resistance to immune
checkpoint blockade occurring in a substantial proportion
of patients enrolled in clinical trials – often months or
years after an initial meaningful response – should come as
a sobering reminder of the need to continuously identify
resistance pathways to overcome.2 As immunotherapy is
incorporated into routine clinical practice, an increase in
the number of reported cases of relapse is to be expected.
Ipso facto, it is imperative to consider combination or
sequential strategies to overcome such resistance. In a
recent review article by Syn et al., the complexity of mech-
anisms that abet the formation of so-called “immunoresis-
tant niches” have been detailed.2 The authors propose a
conceptual framework encompassing 10 major hallmarks
of cancer immunoresistance (numbered in parentheses in
the succeeding paragraphs). It appears that mechanisms of
acquired resistance parallel those that underpin intrinsic
resistance to immunotherapy, although subtle contextual
nuances in the basis of the two phenotypes may be
appreciated.
The ﬁrst overarching mechanism proposed is that of a
defective tumor immunorecognition system, which sub-
sumes the following concepts: (i) disabled antigen presen-
tation, (ii) limited neoantigen repertoire (which itself could
be a consequence of immunoediting), and (iii) insufﬁcient
diversity and abundance of CD8 T-cells. Indeed, these
three ideas correspond to the individual steps of tumor
antigen presentation and priming of the adaptive immune
system, and the notion that defective tumor
immunorecognition restrains both natural and therapy-
elicited immunosurveillance is now well-recognized.3 Cur-
rent clinical research focuses on the combination of
immune checkpoint inhibitors and (DNA-damaging) cyto-
toxic chemotherapeutic agents. It may seem counterintui-
tive to employ cytotoxic agents in a strategy aimed at
enhancing T-cell activation and clonal expansion, as it
could potentially attenuate immune cells and responses
required for antitumor immunity. However, pre-clinical
studies have demonstrated that DNA-damaging agents, in
addition to their direct cytotoxic effects, have the added
beneﬁt of promoting immunogenicity. Enhanced immuno-
genicity may be achieved through two mechanisms –
directly promoting antigenicity of the tumor through the
disruption of DNA, and indirectly lifting immunosuppres-
sion within the tumor microenvironment.4 Blank et al.
have described a spectrum of tumor immunogenicity –
“inﬂammatory” tumors tend to be responsive to check-
point inhibition, limiting combination therapy usage to
tumors that have acquired resistance, whereas “immune
desert”-type tumors probably require the complementary
effect of combination therapy to achieve signiﬁcant clinical
effect.5
Nevertheless, cancer cells have a range of adaptive pro-
grams to limit DNA damage induced by genotoxic agents,
which are linked to innate and adaptive immunity. Inhibit-
ing these DNA-repair mechanisms may possibly enhance
tumor foreignness,4 but may come at the price of dampen-
ing the effects of immune checkpoint inhibitors. Combina-
tion therapy of anti-DNA-repair agents and immune
checkpoint inhibitors may be promising, because of the
potential for reducing toxicity associated with the latter.4
A second overarching mechanism proposed by Syn et al.
relates to the tumor microenvironment and neovasculature,
and encompasses the following three concepts: (iv) the
immune contexture (i.e. extent of T-cell inﬁltration and
reactivity), (v) deregulation of immunometabolism, and
(vi) angiogenesis.2 Indeed, cancer cells interact within a
dynamic and stochastic microenvironment with hetero-
typic cell types. An abundance of literature has emerged in
recent years describing how these ostensibly “normal” cells
in the tumor microenvironment contribute to spatially-
limited “immunoresistant niches.” For instance, proangio-
genic VEGF signaling features in tumors that are resistant
to immunotherapy, and the tumor neovasculature may
play a role in selectively culling assailing CD8 T-cells while
posing a formidable physical barrier to their extravasation.
Crucially, vascular normalization with anti-angiogenic
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therapies has shown promise in improving lymphocyte
trafﬁcking across the endothelium and reversing immuno-
therapy resistance. Emerging evidence also suggests that
derangements of T-cell immunometabolism – particularly
as a result of hypoxia, high concentrations of tumor-
derived lactic acid, and scarcity of glucose and amino acids
in the tumor microenvironment – can encumber the acti-
vation and effector functions of antitumor T-lymphocytes.
Identifying biomarkers pertaining to the tumor microenvi-
ronment to predict response or resistance to immunother-
apy thus represents a necessary, albeit challenging, logical
next step.
Aside from the contributions of defective tumor immu-
norecognition, the tumor microenvironment, and neovas-
culature to immunotherapeutic resistance, a further four
resistance mechanisms were enumerated: (vii) insensitivity
to immune effector molecules (e.g. IFN-γ and FasL),
(viii) tumor plasticity and stemness, (ix) the enteric micro-
biome, and (x) co-option of alternative immune check-
points. The role of epithelial-to-mesenchymal transition
(EMT) in fostering tumor plasticity is less well known and
warrants further discussion. Studies conducted in the past
have promulgated the notion that inﬂammation-driven
tumor plasticity, which may occur through EMT programs,
is partly responsible for mediating therapeutic resistance to
cytotoxic drugs, targeted therapies, and radiation therapy.
Thus, recent ﬁndings that inﬂammatory immune inﬁltrates
may also paradoxically engender resistance to adoptive T-
cell transfer or checkpoint blockade immunotherapy
through EMT programs.2 In addition, the role of gut
microbiota in dictating a response to immunotherapy has
become the subject of intensive research in the past few
months, with multiple studies reporting correlations
between various microbial constellations with immuno-
therapy efﬁcacy. Unfortunately, these associations have not
been consistent across studies, and various points of con-
jecture exist as to how gut bacteria may modify immuno-
therapy response and resistance. Until mechanisms of how
enteric bacteria modulate the adjuvanticity of immune
response are fully elucidated, it seems less likely that ratio-
nal approaches can be devised to harness the enteric
microbiome to salvage resistance to cancer
immunotherapy.
Enumerating the multifactorial mechanisms through
which resistance to immune checkpoint blockade occurs
may only be half of the battle. We have discussed the
importance of having frameworks to understand the mech-
anisms at play in developing resistant tumors, and having
biomarkers to predict the likelihood and gauge the extent
of response, if any. Identifying these functional barriers to
immunotherapy is critical to protract the efﬁcacy of immu-
notherapy, or enable immune checkpoint blockage on pre-
viously intractable malignancies. It is also important to
consider other current issues and future perspectives in the
management of patients treated with immunotherapy. The
wide range of adverse effects documented with immuno-
therapy, from endocrinopathies to gastrointestinal toxic-
ities and autoimmune inﬂammatory conditions, hints at
possible pharmacogenomic underpinnings and represents a
unique and emerging challenge. For future research, it is
important that clinical development of immune checkpoint
blockade continues to embrace parallel developments in
genomics, epigenomics, and precision medicine. Like tar-
geted therapies, we envisage that optimal use of cancer
immunotherapy will hinge on the identiﬁcation of mecha-
nistic biomarkers of response and resistance, and this in
turn underscores the importance of conceptual frameworks
for conceiving the cancer-immunity interplay, and to guide
research agendas over the next decade.
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